Accuray and Samsung NeuroLogica Advance Volumetric Imaging Collaboration for the Accuray CyberKnife® Platform
Accuray (ARAY) and Samsung NeuroLogica have partnered to advance volumetric imaging for the CyberKnife System. The collaboration aims to enhance treatment efficiency and decision-making, addressing customer priorities. Key clinicians highlighted the potential benefits for various cancer treatments. The partnership is part of Accuray's strategy to accelerate innovation through targeted collaborations.
How this was made

The 30-second read
Why it matters
The deal expands Accuray's imaging capabilities, potentially improving treatment precision and market competitiveness.
Market read
A strategic partnership that could enhance product differentiation but lacks immediate financial impact.
What to watch
Regulatory approvals and clinical validation timelines could delay any material impact.
Background
Accuray (NASDAQ: ARAY) provides robotic radiosurgery systems; Samsung NeuroLogica supplies mobile CT imaging. The collaboration was announced at the ASTRO meeting.
Ticker impact
Accuray announced a new collaboration with Samsung NeuroLogica to develop volumetric imaging for its CyberKnife platform, a first‑time disclosure of this partnership.
likely neutral to slight upside as the market prices in the strategic collaboration
The announcement is new and strategic, yet lacks concrete financial terms or timelines, limiting immediate price pressure.
Market effects
May signal increased focus on imaging integration within the radiation oncology equipment sector.
Primarily U.S. biotech/medical‑device market; limited broader regional effect.
Limited to companies developing combined imaging‑therapy solutions.
Counterpoint
Without clear revenue or product milestones, the partnership could be a distraction rather than a catalyst.
Key entities
- CompanyAccuray Incorporated
Developer of the CyberKnife robotic radiosurgery platform.
- CompanySamsung NeuroLogica
Provider of mobile CT and volumetric imaging technology.




